ライフサイエンスコーパス: basal cell

1 n (residual embryonic cells and transitional basal cells).

2 antly enriched for genes expressed in airway basal cells.

3 cell types, as well as six subpopulations of basal cells.

4 alveolar epithelial type II (AT2) or KRT5(+) basal cells.

5 cells, whereas basal cells divided only into basal cells.

6 H3N2 was also detected in rare goblet and basal cells.

7 d in reserve, and mitotically active globose basal cells.

8 pithelia derived from normal human bronchial basal cells.

9 located at the interface between luminal and basal cells.

10 that comprised about ten per cent of KRT5(+) basal cells.

11 i-ciliated and a layer of Keratin-5-positive basal cells.

12 l cells are molecularly distinct from Krt15- basal cells.

13 of several epithelia, but suppressed in p63+ basal cells.

14 inhibition allowed rapid expansion of airway basal cells.

15 entiation of airway progenitors into KRT5(+) basal cells.

16 clear halo was visible within the epithelial basal cells.

17 P include macrophages, alveolar type II, and basal cells.

18 2-HRAS* expression occurs primarily in supra-basal cells.

19 bnormally segregated to the apical cortex of basal cells.

20 ferentiate into luminal, neuroendocrine, and basal cells.

21 Lutheran/basal cell adhesion molecule (Lu/BCAM) promotes tumor ce

22 integrin Myospheroid, which is necessary for basal cell adhesion, is mislocalized in Sac1(ts) retinas

23 trachea during epithelial regeneration from basal cells after injury.

24 including principal cells, clear cells, and basal cells, along with associated support cells that in

25 M(+) luminal progenitors, which express both basal cell and luminal cell-enriched genes.

26 intercellular spaces (confirmed by CLE), and basal cell and papillary hyperplasia developed without s

27 cyte-predominant esophageal inflammation and basal cell and papillary hyperplasia without loss of sur

28 Also evaluated were changes in epithelial basal cell and papillary hyperplasia, surface erosions,

29 Basal cell and squamous cell carcinomas of the skin are

30 tnnb1 in the mesenchyme leads to the loss of basal cells and cartilage, concomitant with reduced tran

31 ferentiation of keratin 5-positive (Krt5(+)) basal cells and ectopic expression of squamous-like diff

32 s, identifies functional heterogeneity among basal cells and establishes a facile in vitro organoid m

33 ers differentiated from primary human airway basal cells and examined by advanced imaging.

34 PA200 was upregulated in hyperplastic basal cells and myofibroblasts of fibrotic lungs from pa

35 ter injury versus controls, including larger basal cells and nuclei, more persistent basal and ectopi

36 context-dependent functions, is produced by basal cells and restrains progenitor cell proliferation.

37 irmed that NOTCH2 maintains undifferentiated basal cells and restricts basal-to-ciliated differentiat

38 18.5, intermediate cells differentiated into basal cells and superficial cells.

39 en activating reserve stem cells (horizontal basal cells) and Neurogenin1 (+) immediate neuronal prec

40 an abundant product of normal mammary gland basal cells, and that alpha3(V) ablation in a mouse mamm

41 ks cyclophosphamide-induced intermediate and basal cell apoptosis, likely by phosphorylated AKT, and

42 l cell loss, KGF suppressed intermediate and basal cell apoptosis, likely via AKT signaling.

43 and basal cell development, Nkx2.1(+)p63(+) basal cells are co-present with cartilage nodules in Shh

44 train secretory differentiation.Conclusions: Basal cells are dynamically regulated in disease and are

45 Using RNA-seq, we show that basal cells are extraordinarily transcriptionally dynami

46 riptional profiling demonstrated that Krt15+ basal cells are molecularly distinct from Krt15- basal c

47 ing experiments showed that CC10(+), but not basal, cells are the cells of origin of LSCC in KF mice.

48 club cells, and was absent from ciliated and basal cells as detected via immunohistochemistry.

49 ts from a local increase in BMP5 activity in basal cells as shown by the impaired self-renewal capaci

50 led cells include both proliferative globose basal cells as well as immature OSNs exhibiting the hall

51 Canonical alpha6beta4C expressed in all basal cells, as expected, while alpha6beta4E expressed w

52 T-mTORC1-NFkappaB-MMP9 pathway activation in basal cells, as well as systemic isotonicity, prevents m

53 mammary and prostate glands, are composed of basal cells (BCs) and luminal cells (LCs)(1,2).

54 To identify signals controlling basal cell behavior we screened factors that alter their

55 rom the neural crest, with the secretory and basal cells being of urogenital sinus origin.

56 defective regeneration, fewer cells, larger basal cell bodies and nuclei, paradoxical increases in p

57 luminal cells and an excessive expansion of basal cells, both in vivo and in vitro The inability to

58 sing cells with a decreased number of CK5(+) basal cells but an increase of CK8(+) luminal tumorigeni

59 teins not previously identified in olfactory basal cells but known to be essential for self-renewal i

60 ssay, our group previously demonstrated that basal cells can serve as efficient targets for transform

61 Basal cell cancers (BCCs) are characterized by upregulat

62 airway-like organoids possessing functional basal cells capable of clonal expansion and multilineage

63 Strikingly, basal cell carcinogenesis only occurs when Atp1b1a funct

64 3%]), cutaneous SCC (11 of 21 tumors [52%]), basal cell carcinoma (3 of 4 tumors [75%]), and ACC (5 o

65 s in human skin biopsy samples diagnosed for basal cell carcinoma (BCC) and compared with healthy ski

66 mance of this methodology on differentiating basal cell carcinoma (BCC) and squamous cell carcinoma (

67 Keratinocyte cancers (KCs), including basal cell carcinoma (BCC) and squamous cell carcinoma (

68 f nonmelanoma skin cancer (NMSC), defined as basal cell carcinoma (BCC) and squamous cell carcinoma (

69 tance: Keratinocyte cancers (KCs), including basal cell carcinoma (BCC) and squamous cell carcinoma (

70 ng DSCMs before and after training to detect basal cell carcinoma (BCC) and squamous cell carcinoma (

71 Basal cell carcinoma (BCC) and squamous cell carcinoma (

72 sive skin neoplasm with the features of both basal cell carcinoma (BCC) and squamous cell carcinoma (

73 in cancers using a population-based study of basal cell carcinoma (BCC) and squamous cell carcinomas

74 Basal cell carcinoma (BCC) are common in this age group

75 expression and its clinical significance in basal cell carcinoma (BCC) are unknown to date.

76 The effect of UVR on human basal cell carcinoma (BCC) epidemiology is complex-the i

77 ociation of dietary pattern with the risk of basal cell carcinoma (BCC) is little understood and has

78 Basal cell carcinoma (BCC) is the most common cancer wor

79 Basal cell carcinoma (BCC) is the most common type of sk

80 published squamous cell carcinoma (SCC) and basal cell carcinoma (BCC) nontransplant GWAS.

81 Basal cell carcinoma (BCC) of the skin is the most commo

82 r calcium supplementation alters the risk of basal cell carcinoma (BCC) or invasive cutaneous squamou

83 s between cigarette smoking and incidence of basal cell carcinoma (BCC) or squamous cell carcinoma (S

84 the cancer-associated microRNA-21 (miR21) in basal cell carcinoma (BCC) skin tumors.

85 itor vismodegib is FDA approved for advanced basal cell carcinoma (BCC), and shows promise in clinica

86 a new type of targeted therapy for advanced basal cell carcinoma (BCC), and their long-term effects,

87 he INTU gene is aberrantly elevated in human basal cell carcinoma (BCC), coinciding with increased pr

88 cutaneous squamous cell carcinoma (SCC) and basal cell carcinoma (BCC), in part as a result of immun

89 risk estimates to evaluate the risks of SCC, basal cell carcinoma (BCC), keratinocyte cancers (KCs) o

90 Importance: Rates of skin cancer, including basal cell carcinoma (BCC), the most common cancer, have

91 Basal cell carcinoma (BCC), the most common human cancer

92 us cell carcinoma, and a superficial type of basal cell carcinoma (BCC).

93 moothened (SMO) inhibitor-treated metastatic basal cell carcinoma (BCC).

94 icated for the treatment of locally advanced basal cell carcinoma (laBCC), with an objective response

95 Basal cell carcinoma (n = 8, 50%) was the most common ey

96 Tests on prostate cancer, basal cell carcinoma and breast cancer metastases to axi

97 Hh signaling is upregulated in basal cell carcinoma and medulloblastoma and Hh pathway

98 ns in Smoothened (SMO) have been reported in basal cell carcinoma and medulloblastoma, but are largel

99 ing leads to several malignancies, including basal cell carcinoma and paediatric medulloblastoma(2).

100 Hedgehog signaling, where Ptch1 loss causes basal cell carcinoma and Ptch1;Ptch2 loss disrupts skin

101 de prior CLL for squamous cell carcinoma and basal cell carcinoma and reduced-intensity conditioning

102 ared with surgery for superficial or nodular basal cell carcinoma at low-risk sites in our noninferio

103 Basal cell carcinoma in the very elderly were more commo

104 en's Hospital Oakland Research Institute and Basal Cell Carcinoma Nevus Syndrome Life Support Network

105 Pretransplant basal cell carcinoma of the skin and male genital cancer

106 ed a diagnosis of and were being treated for basal cell carcinoma or squamous cell carcinoma (cases)

107 Multiple hereditary infundibulocystic basal cell carcinoma syndrome (MHIBCC) is a rare genoder

108 icial basal cell carcinoma, 6 weeks; nodular basal cell carcinoma, 12 weeks) or excisional surgery (4

109 o imiquimod 5% cream once daily (superficial basal cell carcinoma, 6 weeks; nodular basal cell carcin

110 In basal cell carcinoma, application of scATAC-seq reveals

111 er, comprising cutaneous squamous (cSCC) and basal cell carcinoma, is the most common malignancy in t

112 rial Fibrillation, High Cholesterol, Asthma, Basal Cell Carcinoma, Malignant Melanoma, and Heart Atta

113 His medical history included basal cell carcinoma, rheumatoid arthritis, and Barrett

114 Basal cell carcinoma, solar keratosis, and colorectal ca

115 immunosuppressed = 8.9 years), 135 (27%) had basal cell carcinoma, squamous cell carcinoma or Bowen's

116 , the most common pediatric brain tumor, and basal cell carcinoma, the most common cancer in the Unit

117 tate and lung adenocarcinoma to melanoma and basal cell carcinoma.

118 um antibodies and cSCC or between betaPV and basal cell carcinoma.

119 elioma, meningioma, renal cell carcinoma and basal cell carcinoma.

120 n the proliferation of colorectal cancer and basal cell carcinoma.

121 t (1 malignancy) also developed a periocular basal cell carcinoma.

122 ncluding medulloblastoma, ameloblastoma, and basal cell carcinoma.

123 use of SMO antagonists for the treatment of basal cell carcinoma.

124 ceptor-7 agonist currently used for treating basal cell carcinoma.

125 unds have been approved for use in Hh-driven basal cell carcinoma.

126 than 200,000 single cells in human blood and basal cell carcinoma.

127 inoma and reduced-intensity conditioning for basal cell carcinoma.

128 uding actinic keratoses and Bowen's disease; basal cell carcinoma; benign keratinocytic lesions inclu

129 procaspase-8) in association with cutaneous basal-cell carcinoma (BCC) and linked to a germline SNP

130 ell carcinoma tumour burden and prevents new basal-cell carcinoma growth in patients with basal-cell

131 ular oedema in six (2%) versus six (1%), and basal-cell carcinoma in 14 (4%) versus nine (2%).

132 The mean number of basal-cell carcinoma lesions at week 73 was reduced from

133 erruption of treatment, which is followed by basal-cell carcinoma recurrence.

134 the smoothened inhibitor vismodegib reduces basal-cell carcinoma tumour burden and prevents new basa

135 Vismodegib reduces basal-cell carcinoma tumour burden in patients with basa

136 is approved for use in adults with advanced basal-cell carcinoma.

137 confirmed, including 9 melanomas (0.5%), 37 basal cell carcinomas (1.9%), and 1 squamous cell carcin

138 way is aberrantly activated in a majority of basal cell carcinomas (BCC).

139 1.41 (1.19-1.67), and 1.57 (0.64-3.86), for basal cell carcinomas (BCCs) and squamous cell carcinoma

140 Basal cell carcinomas (BCCs) depend on Hedgehog (Hh)/Gli

141 herein affected individuals develop multiple basal cell carcinomas (BCCs) of the skin.

142 Basal cell carcinomas (BCCs) rely on Hedgehog (HH) pathw

143 Human basal cell carcinomas (BCCs) very frequently carry p53 m

144 he risk of skin cancer, including melanomas, basal cell carcinomas (BCCs), and squamous cell carcinom

145 maintain maximal Hedgehog pathway output in basal cell carcinomas (BCCs), and we have previously sho

146 sting of squamous cell carcinomas (SCCs) and basal cell carcinomas (BCCs), are the most common human

147 lly all sporadic and Gorlin syndrome-related basal cell carcinomas (BCCs), with loss of function of P

148 ) have a greater risk of developing numerous basal cell carcinomas (BCCs).

149 ) have a greater risk of developing numerous basal cell carcinomas (BCCs).

150 = 9.8; 95% confidence interval = 7.7-12.3), basal cell carcinomas (incidence rate ratio = 2.5; 95% c

151 d specificity of 89-99% for the detection of basal cell carcinomas and can potentially serve as a rap

152 e reveals that dermoscopy can help delineate basal cell carcinomas before surgical removal but that i

153 which numerous indolent, well-differentiated basal cell carcinomas develop primarily on the face and

154 In skin, premalignant basal cell carcinomas form 'buds', while invasive squamo

155 t of the signature genes for human prostatic basal cell carcinomas in the above prostate tumors.

156 odalities to help delineate tumor margins of basal cell carcinomas in the setting of Mohs micrographi

157 nd demonstrate that BSCs likely originate as basal cell carcinomas that partially squamatize through

158 Risk factors for basal cell carcinomas were chronic lymphocytic leukemia

159 n lesions (8 nevi, 8 seborrheic keratoses, 7 basal cell carcinomas, 7 melanomas, 4 hemangiomas, 4 der

160 ceous differentiation, including a subset of basal cell carcinomas.

161 UVR in sunlight causes mutations that drive basal cell carcinomas.

162 nderlie the development of infundibulocystic basal cell carcinomas.

163 as well as renal, breast, lung, gastric, and basal cell carcinomas.

164 on the incidence of new surgically eligible basal-cell carcinomas after 3 months of treatment.

165 y, had serious adverse events, including two basal-cell carcinomas and one major cardiovascular adver

166 ndrome with at least ten surgically eligible basal-cell carcinomas at the Children's Hospital Oakland

167 baseline in the number of clinically evident basal-cell carcinomas at week 73.

168 mean reduced rate of new surgically eligible basal-cell carcinomas compared with patients randomly as

169 d the development of new surgically eligible basal-cell carcinomas compared with placebo (0.4 [SD 0.2

170 Fewer new surgically eligible basal-cell carcinomas developed in patients receiving vi

171 ing (mean 0.6 [0.72] new surgically eligible basal-cell carcinomas per patient per year vs 1.7 [1.8]

172 lacebo (0.4 [SD 0.2] new surgically eligible basal-cell carcinomas per patient per year vs 30.0 [7.8]

173 (n=15; two [SD 0.12] new surgically eligible basal-cell carcinomas per patient per year vs 34 [1.32]

174 er year vs 34 [1.32] new surgically eligible basal-cell carcinomas per patient per year, p<0.0001).

175 er year vs 1.7 [1.8] new surgically eligible basal-cell carcinomas per patient per year, p<0.0001).

176 r year vs 30.0 [7.8] new surgically eligible basal-cell carcinomas per patient per year, p<0.0001).

177 Patients with multiple basal-cell carcinomas, including those with basal-cell n

178 al, we enrolled adult patients with multiple basal-cell carcinomas, including those with basal-cell n

179 onfirmed and at least six clinically evident basal-cell carcinomas.

180 ib dosing regimens in patients with multiple basal-cell carcinomas.

181 long-term regimens in patients with multiple basal-cell carcinomas.

182 ehog signalling underlies the development of basal-cell carcinomas.

183 junctions and increased proliferation in the basal cell compartment.

184 ike engulfment and entrainment of underlying basal cells, constituting a tumor-suppressive effect.

185 OPN expression was up-regulated in submerged basal cells cultures exposed to cigarette smoke (CS) ext

186 t with the association between cartilage and basal cell development, Nkx2.1(+)p63(+) basal cells are

187 overexpression of LXN in prostate epithelial basal cells did not affect cell fate, LXN overexpression

188 pressing epithelial progenitors and promotes basal cell differentiation in the cartilaginous airways.

189 ells still gave rise to basal cells, whereas basal cells divided only into basal cells.

190 in in vivo leads to misorientation of apical-basal cell division in nephron tubules.

191 that beta-catenin signaling is activated in basal cells during early pregnancy, and demonstrate that

192 cells and tested their potential to produce basal cells during tumorigenesis.

193 o had (less severe) regeneration defects and basal cell endoreplication 3 days after cyclophosphamide

194 Fgfr2KO mice had evidence of pathologic basal cell endoreplication associated with absent phosph

195 er cyclophosphamide exposure from pathologic basal cell endoreplication.

196 cible developmental trajectory: initiated in basal cells exhibiting an epithelial-to-mesenchymal tran

197 Prostatic basal cells express p63 and are able to differentiate in

198 cally constricting cells to undergo aberrant basal cell extrusion and cell intercalation.

199 tion period of 6 hours, but we observed that basal cells flattened to cover the basement membrane.

200 to 6 hours and apoptosis in intermediate and basal cells from 4 to 24 hours was observed after cyclop

201 Consistent with this profile, basal cells functionally exhibit intrinsic stem-like and

202 Cs) and some among the population of globose basal cells (GBCs) are stem cells, but the two types pla

203 Of clinical relevance, the basal cell gene-expression profile is enriched in advanc

204 Although the prostate basal cells have been shown to directly generate tumor c

205 Type IV cells (nonproliferative "basal cells") have a nucleus in the lower quarter of the

206 The horizontal basal cell (HBC) is a dormant tissue-specific stem cell

207 Both horizontal basal cells (HBCs) and some among the population of glob

208 pairs proliferation of progenitor horizontal basal cells (HBCs) and subsequent neuronal differentiati

209 of two stem cell populations: the horizontal basal cells (HBCs), which are quiescent and held in rese

210 ssion is activated in a subset of horizontal basal cells (HBCs), which repopulate all microvillar cel

211 eed to better understand the contribution of basal cell hyperplasia and associated mucosecretory dysf

212 on of epithelial eosinophilia in addition to basal cell hyperplasia and vascular remodeling.

213 d differentiation of human iPSCs into airway basal cells ("iBCs"), a population resembling the stem c

214 ohistochemistry showed an increase in airway basal cells in BAL and tissues of IPF compared with cont

215 ortality unmasks a potential role for airway basal cells in IPF.

216 Basal cells in pseudostratified epithelia display a sing

217 initiate actin polarization and migration of basal cells in their native epithelial context in vivo,

218 ovide evidence that the p63(+)KRT5(+)KRT7(+) basal cells in this zone are the cells of origin for mul

219 e alters the differentiation of small airway basal cells in vitro.

220 nar respiratory epithelial cells, but not of basal cells, in both ex vivo respiratory mucosal explant

221 Secretory primed basal cells include an overlapping molecular signature w

222 Measurements and Main Results: We found that basal cells included multipotent and secretory primed su

223 molecular and functional phenotype of airway basal cells, including the capacity to self-renew or und

224 that stimulated differentiation of prostatic basal cells into transformation-preferable luminal cells

225 indicating that the function of the corneal basal cells is retained.

226 ing, a known negative regulator of embryonic basal cells, is also necessary for maintenance of the pr

227 uency of marked atypia on melanocytes in the basal cell layer; it presented with lower ABCD Total Der

228 es, ISH and qPCR revealed Ddr1 expression in basal cell layers of the oral epithelia and in immune ce

229 nactivation of these genes using Ad-K5cre in basal cells leads to the development of SCLC, thus diffe

230 be replicated using LAE and SAE immortalized basal cell lines derived from healthy nonsmokers.Conclus

231 Here we show that AR is dispensable for basal cell maintenance, but is cell-autonomously require

232 lls, reduced proportions of SAE ciliated and basal cells, markedly abnormal SAE and alveolar macropha

233 nal characteristics, such as p63(+) cells (a basal-cell marker) showing luminal-like morphology, or c

234 The abnormal epithelium expressed basal cell markers, including tumor protein 63, cytokera

235 In response to primary basal cell medium, NKX2-1(GFP+)/TP63(tdTomato+) cells di

236 on of membrane pores through both apical and basal cell membrane layers that reseal along their later

237 ither bulk or FACS-sorted single luminal and basal cells), metastatic prostate cancer lesions and cir

238 ost BCCs are sporadic, rare individuals with basal cell nevus syndrome (BCNS) harbor germline defects

239 Patients with basal cell nevus syndrome (BCNS) have a greater risk of

240 Importance: Patients with basal cell nevus syndrome (BCNS) have a greater risk of

241 nical follow-up time, immunosuppression, and basal cell nevus syndrome status.

242 .89-16.97; P < .001), accounting for age and basal cell nevus syndrome status.

243 ls, without other features characteristic of basal cell nevus syndrome.

244 ntrolled, phase 2 trial in patients with the basal-cell nevus (Gorlin) syndrome indicating that the s

245 basal-cell carcinomas, including those with basal-cell nevus (Gorlin) syndrome, need extended treatm

246 l we enrolled patients aged 35-75 years with basal-cell nevus syndrome with at least ten surgically e

247 nt assignment was stratified by diagnosis of basal-cell nevus syndrome, geographical region, and immu

248 basal-cell carcinomas, including those with basal-cell nevus syndrome, who had one or more histopath

249 basal-cell carcinoma growth in patients with basal-cell nevus syndrome.

250 ell carcinoma tumour burden in patients with basal-cell nevus syndrome.

251 lude an overlapping molecular signature with basal cells obtained from the distal lung tissue of IPF

252 identified 581 SMNs (excluding squamous and basal cell of skin) in 499 individuals.

253 polarity remodeling occurs in proliferative basal cells of mammalian epidermis whereupon cell divisi

254 we found that deletion of Fgfr1 or Spry2 in basal cells of the adult mouse trachea caused an increas

255 t primary cilia are predominantly present on basal cells of the mouse corneal epithelium (CE) through

256 3a mRNA and GFP are expressed within globose basal cells of the olfactory and vomeronasal epithelium

257 discuss potential cells of origin, including basal cells of the squamous epithelium, cells of esophag

258 Basal cells of WTs and epidermoid cells of MECs were str

259 that luminal cells are capable of producing basal cells on activation of either polyoma middle T ant

260 ession in a subset of luminal cells and rare basal cells opposes BMP7 to promote ductal branching.

261 re also described that promote enrichment of basal cells organized into multiple layers surrounding a

262 re able to differentiate into AT1 cells, and basal cell organoids developed lumens lined with differe

263 Modulation of basal cell plasticity may represent a relevant target fo

264 The roles of Scrib and Lgl1 in apical-basal cell polarity have been studied extensively, but l

265 morula stage, outer cells acquire an apical-basal cell polarity, with expression of atypical protein

266 d that the Krt15 promoter marks a long-lived basal cell population able to self-renew, proliferate, a

267 is highly expressed in MaSC-enriched mammary basal cell population and in mammary tumors, and is regu

268 to show that this squamous-columnar junction basal cell population serves as a source of progenitors

269 onal expansion of single human cells and for basal cell populations from epithelial tissues from all

270 ll-cell communication modeling suggests that basal cell populations serve as crucial signaling hubs t

271 ables robust expansion of primary epithelial basal cell populations.

272 Strikingly, basal cells preferentially express gene categories assoc

273 ressed in both basal and luminal cells, with basal cells preferentially expressing acetylated Klf5.

274 echanistically, ANO1-dependent regulation of basal cell proliferation was associated with modulation

275 other receptor tyrosine kinases and restrain basal cell proliferation.

276 Basal cells provide structural and contractile support,

277 e population, whereas Types II, III, and IV (basal cells) represent 19, 15, and 14%, respectively.

278 FGF receptor 2 (FGFR2) in adult mouse airway basal cells results in self-renewal and differentiation

279 ful cultures were prepared using adult mouse basal cells selected for expression of c-KIT.

280 expression of a key transcription factor for basal cell self-renewal and differentiation: SOX2.

281 f AR and SOX2 in the expression of prostatic basal cell signature genes.

282 tocrit levels, and a higher incidence of non-basal-cell skin cancers than placebo.

283 M5B is involved in regulation of luminal and basal cell specific gene expression in breast cancers.

284 We show that in airway basal cells, SPRY2 is post-translationally modified in r

285 tinct stages in the progression from globose basal cell stem cells to fully mature OSNs.

286 toward the expansion of the secretory primed basal cell subset in IPF.

287 used to investigate functional properties of basal cell subtypes.Measurements and Main Results: We fo

288 so leads to significantly reduced numbers of basal cells, supporting the importance of Wnt/Fgf crosst

289 uamous epithelium comprised of proliferative basal cells that differentiate while migrating toward th

290 lly coupled to the basal layer by peripheral basal cells that extend apically and centripetally while

291 The GBC population includes the basal cells that proliferate in the uninjured OE and is

292 atifying divisions, allowing flexibility for basal cells to adapt to the needs of the developing tiss

293 cate the long axis orientation of interphase basal cells to neighbouring basal mitoses so that they a

294 as a transcriptional regulator in prostatic basal cell tumors.

295 erial contain the differentiated luminal and basal cell types, whereas organoids derived from prostat

296 barrier, fail to mature in Pparg mutants and basal cells undergo squamous-like differentiation.

297 Presence of airway basal cells was tested by immunohistochemistry and flow

298 Human airway basal cells were differentiated and cultured at air-liqu

299 ow but intermediate cells still gave rise to basal cells, whereas basal cells divided only into basal

300 idermis revealed a patterned distribution of basal cells with pulsatile ERK activity, and down-regula